This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Network Pharmacology-Based Study on the Mechanism of Pinellia ternata in Asthma Treatment
Yanmin Lyu
Shandong Academy of Medical Sciences
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8232-679X
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Pinellia ternata (PT), a medicinal plant, has had an extensive application in the treatment of asthma in China, whereas its underlying pharmacological mechanisms remain unclear.
Methods: Firstly, the therapeutic effect of PT was verified by an animal experiment. Secondly, a network pharmacology method was adopted to collect activated components of PT from Traditional Chinese Medicine Systems Pharmacology Database and Analysis (TCMSP); binding targets of PT were assessed by exploiting Pharmmapper website; asthma-related targets were collected, and Target-Target interaction networks were built. Subsequently, critical nodes exhibiting high-possibility were identified as the hub nodes in the network, which employed to conduct GeneOntology (GO) comment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment analysis. Finally, the tissue expression profiles and single-cell RNA sequencing (scRNA-Seq) data of candidate genes were identified by Gene Expression Omnibus database (GEO) and PanglaoDB databases.
Results: In animal experiments, PT could alleviate the allergic response of mice by inhibiting the activation of T-helper type 2 (TH2) cells and the secretion of IL-4 and IL-5. Subsequently, 57 achievable targets of PT on asthma were confirmed as hub nodes, included candidate genes matrix metalloproteinase-2 (MMP2) and nuclear receptor subfamily 3 group C member 1(NR3C1). Moreover, according to transcriptome RNA sequencing data from lung tissues of allergic mice compared to normal mice, mRNA level of MMP2 was up-regulated (P<0.001), and mRNA level of NR3C1 was no significant difference (P=0.0749). Finally, we compared their levels of expression and distributions to those present in the single-cell level.
Conclusions: With network pharmacology, our study provides candidate genes that may be either used for future studies related to diagnosis/prognosis or as targets for asthma management. Besides, more attention should be paid to methods of identifying the origin of these genes and determining their expression at the single-cell level.
Keywords
asthma, hub nodes, network pharmacology, Pinellia ternata, scRNA-Seq
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 04 Jun, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Clinical Pharmacology
Learn more about our company.
This is a preprint. It has not completed peer review.
Research
Network Pharmacology-Based Study on the Mechanism of Pinellia ternata in Asthma Treatment
Yanmin Lyu
Shandong Academy of Medical Sciences
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8232-679X
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 04 Jun, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Clinical Pharmacology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Pinellia ternata (PT), a medicinal plant, has had an extensive application in the treatment of asthma in China, whereas its underlying pharmacological mechanisms remain unclear.
Methods: Firstly, the therapeutic effect of PT was verified by an animal experiment. Secondly, a network pharmacology method was adopted to collect activated components of PT from Traditional Chinese Medicine Systems Pharmacology Database and Analysis (TCMSP); binding targets of PT were assessed by exploiting Pharmmapper website; asthma-related targets were collected, and Target-Target interaction networks were built. Subsequently, critical nodes exhibiting high-possibility were identified as the hub nodes in the network, which employed to conduct GeneOntology (GO) comment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment analysis. Finally, the tissue expression profiles and single-cell RNA sequencing (scRNA-Seq) data of candidate genes were identified by Gene Expression Omnibus database (GEO) and PanglaoDB databases.
Results: In animal experiments, PT could alleviate the allergic response of mice by inhibiting the activation of T-helper type 2 (TH2) cells and the secretion of IL-4 and IL-5. Subsequently, 57 achievable targets of PT on asthma were confirmed as hub nodes, included candidate genes matrix metalloproteinase-2 (MMP2) and nuclear receptor subfamily 3 group C member 1(NR3C1). Moreover, according to transcriptome RNA sequencing data from lung tissues of allergic mice compared to normal mice, mRNA level of MMP2 was up-regulated (P<0.001), and mRNA level of NR3C1 was no significant difference (P=0.0749). Finally, we compared their levels of expression and distributions to those present in the single-cell level.
Conclusions: With network pharmacology, our study provides candidate genes that may be either used for future studies related to diagnosis/prognosis or as targets for asthma management. Besides, more attention should be paid to methods of identifying the origin of these genes and determining their expression at the single-cell level.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6